糖皮质激素毒性指数-代谢域:糖皮质激素毒性指数的简化版本——ADVOCATE 试验数据的回顾性分析
该研究为 ADVOCATE 试验的事后分析,旨在比较糖皮质激素毒性指数(GTI)与简化版 GTI-代谢域(GTI-MD)在评估糖皮质激素毒性方面的相关性及区分能力。结果显示 GTI-MD 与 GTI 相关性良好,并能区分 avacopan 组与泼尼松组的毒性差异,且验证队列结果一致。
要点
- GTI-MD 与 GTI 的累积恶化评分(CWS)在 ADVOCATE 试验中 Spearman 秩相关系数为 0.78(95%CI 0.75-0.81;p<0.0001)。
- GTI-MD 在 13 周和 26 周均可区分 avacopan 组与泼尼松组的糖皮质激素毒性差异。
- GTI-MD 评分 0 对应其他 GTI 域毒性可能性低。
核心结论
- GTI-MD 与完整 GTI 相关性良好,可纳入常规临床工作流程而无需临床医生额外投入。
- 在电子病历系统背景下使用 GTI-MD 可能有助于临床医生纵向监测糖皮质激素毒性,以预防慢性治疗相关损害的负担并降低卫生系统的长期成本。
研究设计与样本
- ADVOCATE 试验的事后分析,该试验为随机、双盲、双模拟、3 期试验,在抗中性粒细胞胞浆抗体相关性血管炎患者中以 avacopan 替代标准泼尼松减量方案。
- 计算 GTI-MD 各域(包括 GTI 的 BMI、葡萄糖耐量、血压和脂质代谢域)的累积恶化评分(CWS)和总体改善评分(AIS),以检验其区分 avacopan 组与泼尼松组糖皮质激素毒性的能力。
- 验证集包括两个额外疾病队列,一个为哮喘患者,另一个为自身免疫性大疱性疾病患者。
主要发现
- ADVOCATE 试验意向性治疗人群 330 例中,第 13 周有 321 例(97%)完整数据,第 26 周有 307 例(93%),这些个体的数据纳入事后分析。
- ADVOCATE 试验中,avacopan 组 166 例中男性 98 例(59%)、女性 68 例(41%);泼尼松组 164 例中男性 88 例(54%)、女性 76 例(46%);平均年龄 avacopan 组 61.2 岁(SD 14.6),泼尼松组 60.5 岁(14.5)。
- 验证队列包括 159 例患者(89 例糖皮质激素依赖性哮喘,其中男性 40 例[45%]、女性 49 例[55%];70 例自身免疫性大疱性皮肤病,其中男性 30 例[43%]、女性 40 例[57%])。
- ADVOCATE 试验中,GTI-MD CWS 与 GTI CWS 在治疗组合并后的 Spearman 秩相关系数为 0.78(95%CI 0.75-0.81;p<0.0001);AIS 的相应相关系数为 0.73(95%CI 0.69-0.77;p<0.0001)。
- GTI-MD 在 13 周和 26 周均能区分两组糖皮质激素毒性:平均 GTI-MD CWS avacopan 组低于泼尼松组(13 周 15.9 vs 23.0,p=0.0010;26 周 26.7 vs 31.7,p=0.0092);GTI-MD AIS 亦一致(13 周 2.5 vs 13.0,p=0.0003;26 周 4.4 vs 10.1,p=0.027)。
关键数值与推荐
- GTI-MD 包括 GTI 的 BMI、葡萄糖耐量、血压和脂质代谢域。
- ADVOCATE 试验中 GTI-MD CWS 与 GTI CWS 的 Spearman 秩相关系数为 0.78(95%CI 0.75-0.81;p<0.0001),AIS 为 0.73(95%CI 0.69-0.77;p<0.0001)。
- 验证集中 GTI-MD CWS 与 GTI CWS 的 Spearman 秩相关系数为 0.61(95%CI 0.50-0.70;p<0.0001),AIS 为 0.58(95%CI 0.47-0.68;p<0.0001)。
- 13 周平均 GTI-MD CWS avacopan 组 15.9 vs 泼尼松组 23.0(p=0.0010);26 周 26.7 vs 31.7(p=0.0092)。
- 13 周平均 GTI-MD AIS avacopan 组 2.5 vs 泼尼松组 13.0(p=0.0003);26 周 4.4 vs 10.1(p=0.027)。
临床怎么用
- 原文指出 GTI-MD 与完整 GTI 相关性良好,可纳入常规临床工作流程而无需临床医生额外投入。
- 原文提出在电子病历系统背景下使用 GTI-MD 可能有助于临床医生纵向监测糖皮质激素毒性,以预防慢性治疗相关损害的负担并降低卫生系统的长期成本。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Quantifying glucocorticoid toxicity is crucial to efforts to reduce it. The Glucocorticoid Toxicity Index (GTI) measures toxicity effectively in clinical trials by calculating two scores: the cumulative worsening score (CWS) and the aggregate improvement score (AIS). However, in clinical practice, high patient volumes limit the time available for standardised assessments. We aimed to compare the GTI with an abbreviated version of the GTI, the GTI-Metabolic Domains (GTI-MD), which could help to address this issue by using data that are collected easily at routine visits and do not require additional effort from clinicians. METHODS: We did a post-hoc analysis of data from ADVOCATE, a randomised, double-blind, double-dummy, phase 3 trial in which avacopan replaced a standard prednisone taper in patients with antineutrophil cytoplasmic antibody-associated vasculitis. We calculated the cumulative worsening score (CWS) and aggregate improvement score (AIS) for each domain of the GTI-MD-comprising the BMI, glucose tolerance, blood pressure, and lipid metabolism domains of the GTI-to test its ability to differentiate the avacopan and prednisone groups by glucocorticoid toxicity. Data from two additional disease cohorts, one comprising patients with asthma and the other comprising patients with autoimmune blistering disease, constituted the validation set. FINDINGS: Complete data were available for 321 (97%) of the 330 participants comprising the intention-to-treat population in the ADVOCATE trial at week 13, and 307 (93%) at week 26; data from these individuals were included in our post-hoc analysis. In ADVOCATE, 98 (59%) of 166 participants in the avacopan group were men and 68 (41%) were women, 88 (54%) of 164 in the prednisone group were men and 76 (46%) were women; the mean age of participants was 61·2 years [SD 14·6] in the avacopan group and 60·5 years [14·5] in the prednisone group. The validation cohort included 159 patients (89 with glucocorticoid-dependent asthma, of whom 40 [45%] were men and 49 [55%] were women, and 70 with autoimmune blistering disease of the skin, of whom 30 [43%] were men and 40 [57%] were women). The Spearman's rank correlation coefficient in ADVOCATE for the GTI-MD CWS with the GTI CWS for the treatment groups combined was 0·78 (95% CI 0·75-0·81; p<0·0001). The corresponding correlation for the AIS was 0·73 (0·69-0·77, p<0·0001). The GTI-MD distinguished the groups by glucocorticoid toxicity at both 13 weeks and 26 weeks. The mean GTI-MD CWS was lower in the avacopan group than in the prednisone group, consistent with less toxicity (15·9 vs 23·0 at 13 weeks [p=0·0010]; 26·7 vs 31·7 at 26 weeks [p=0·0092]). The GTI-MD AIS values were also consistent with less toxicity in the avacopan group (2·5 vs 13·0 at 13 weeks [p=0·0003], 4·4 vs 10·1 at 26 weeks [p=0·027]). A GTI-MD score of 0 corresponded to a low likelihood of toxicity in the other GTI domains. In the validation set, the Spearman's rank correlation coefficient for the GTI-MD CWS with the GTI CWS was 0·61 (95% CI 0·50-0·70; p<0·0001) and the corresponding correlation for the AIS was 0·58 (0·47-0·68; p<0·0001). INTERPRETATION: The GTI-MD correlates well with the full GTI and could be incorporated readily into routine clinic workflows without additional input from the clinician. Using the GTI-MD on the background of electronic medical records systems could help clinicians to monitor glucocorticoid toxicity longitudinally, with the goals of preventing the burden of chronic, treatment-related harms and reducing long-term costs to health systems. FUNDING: ChemoCentryx.
引用
- Patel NJ, Jayne DRW, Merkel PA, et al. The Glucocorticoid Toxicity Index-Metabolic Domains, an abridged version of the Glucocorticoid Toxicity Index: post-hoc analysis of data from the ADVOCATE trial. Lancet Rheumatol. 2023. PMID: 38251552. doi:10.1016/S2665-9913(23)00131-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。